Two stocks in Healthcare
Johnson & Johnson vs Medtronic: profit, growth, debt and price compared
Medtronic is stronger on 4 of 7 figures: sales growth, price for its expected profit, dividend and price trend. Johnson & Johnson is stronger on 2: profit margin and debt.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Johnson & JohnsonJNJ | MedtronicMDT | |
|---|---|---|
| Net margin | Stronger: 16.2% | 13.9% |
| Revenue growth, past year | +5.86% | Stronger: +13.73% |
| Debt to equity | Stronger: 54.8% | 55.4% |
| Forward P/E | 23.5× | Stronger: 15.7× |
| Dividend yield | 1.94% | Stronger: 2.83% |
| Analysts | Buy · 22 | Buy · 26 |
| From its 200-day average | +10.2% | Stronger: +12.5% |
Share price over the past year
- Johnson & Johnson+36.3%
- Medtronic−0.1%
18 Nov 202518 Nov 2026
Johnson & Johnson or Medtronic: which is stronger?
- JNJ
Which is more profitable?
Johnson & Johnson keeps more of each sale as profit: 16.2% against 13.9%.
- MDT
Which is growing its sales faster?
Medtronic is growing its sales faster: +13.73% over the past year, against +5.86%.
- JNJ
Which has borrowed less?
Johnson & Johnson has borrowed less: its debt is 54.8% of what its shareholders own, against 55.4% for Medtronic.
- MDT
Which costs less for the profit it is expected to make?
Medtronic costs less for the profit it is expected to make: 15.7× its forward earnings, against 23.5×.
- MDT
Which pays more in dividends?
Medtronic pays more back in dividends for what a share costs: 2.83% a year, against 1.94%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- MDT
Which is in the stronger price trend?
Medtronic's price is in the stronger trend: 12.5% above its 200-day average, against 10.2% above.
What each company does
JNJJohnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Reports results on 26 January 2027
MDTMedtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Reports results on 24 November 2026
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.